Response to: Correspondence on 'Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors' by Säemann and Kronbichler

We thank our colleague Dr Patoulas¹ for pointing out that sodium glucose transporter (SGLT)-2 inhibition (SGLT-2i) could mediate nephroprotection in patients with lupus nephritis (LN) and ANCA-associated vasculitis (AAV) via specific mechanisms within the tubular cell compartment independent of the presence of diabetes mellitus.² As discussed by Dr Patoulas, kidney injury molecule-1 (KIM-1) is affected by SGLT-2i correlating with improvements in albuminuria, a hallmark of chronic kidney damage. KIM-1, however, is not only a mere marker of tubular injury, but it is actively involved in diverse pathogenic actions. Hence, its expression, for example, in diabetic kidney disease accelerates kidney injury via fatty acid uptake coupled with tubular glucose reabsorption in renal proximal tubular cells, resulting in various detrimental stress responses.³ Upregulation of KIM-1 and the ensuing tubular cell responses illustrate the close relationship between diseased glomeruli and subsequent tubulointerstitial fibrosis in response to increased tubular workload, thereby diseases traditionally considered primarily of glomerular origin such as diabetic kidney disease, and also inflammatory diseases such as LN and AAV, illustrate the therapeutic potential of innovative therapies such as SGLT-2i by limiting permanent and progressive damage especially to the tubulointerstitial tissue. The concept of nephron overload has been very recently proposed to be the final result of various and diverse pathogenic insults in most forms of chronic kidney disease.⁴ Since SGLT-2i substantially reduce tubular workload, they belong to the most efficient therapeutic interventions impacting nephron overload, suggesting also significant nephroprotective effects in LN and AAV.

Marcus Säemann ^{1,2}, Andreas Kronbichler ³

¹6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, Vienna, Austria

²Medical School, Sigmund Freud University, Vienna, Austria

³Department of Medicine, University of Cambridge, Cambridge, UK

Correspondence to Dr Marcus Säemann, 6th Medical Department, Nephrology and Dialysis, Clinic Ottakring, VIENNA, Austria; SAEMANNMARCUS@GMAIL.COM

Handling editor Josef S Smolen

Contributors MS wrote and submitted the draft. AK edited the first draft of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Säemann M, Kronbichler A. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2021-221982

Received 20 December 2021

Accepted 22 December 2021

► <http://dx.doi.org/10.1136/annrheumdis-2021-221953>

Ann Rheum Dis 2022;0:1. doi:10.1136/annrheumdis-2021-221982

ORCID iDs

Marcus Säemann <http://orcid.org/0000-0003-2316-449X>

Andreas Kronbichler <http://orcid.org/0000-0002-2945-2946>

REFERENCES

- 1 Patoulas D. Correspondence on 'Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors' by Säemann and Kronbichler. *Ann Rheum Dis* 2021. doi:10.1136/annrheumdis-2021-221953
- 2 Säemann M, Kronbichler A. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. *Ann Rheum Dis* 2021. doi:10.1136/annrheumdis-2021-221474. [Epub ahead of print: 29 Nov 2021].
- 3 Mori Y, Ajay AK, Chang J-H, et al. KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. *Cell Metab* 2021;33:1042–61.
- 4 Luyckx VA, Rule AD, Tuttle KR, et al. Nephron overload as a therapeutic target to maximize kidney lifespan. *Nat Rev Nephrol* 2021. doi:10.1038/s41581-021-00510-7. [Epub ahead of print: 08 Dec 2021].